1. HOME
2. Research Insight
3. Terumo corporation (Japan) and Artivion, Inc. (US) are Leading Players in the Cardiac Tissue Engineering Market

The Cardiac tissue engineering market is projected to reach USD 1,333.6 million by 2029 from USD 621.2 million in 2024, at a CAGR 16.5% from 2024 to 2029. Cardiac tissue engineering combines regenerative cells, biological or synthetic materials, and growth and differentiation factors to regenerate damaged or missing myocardial tissues. This field involves developing and implanting engineered tissues or injecting cells and biomaterials to treat cardiovascular diseases.

The cardiac tisssue engineering market is a highly consolidated market and is dominated by key players. The major players operating in this market Terumo corporation (Japan), Artivion, Inc. (US), Baxter international, Inc. (US), Teijin Limited (Japan), Medtronic Plc. (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Elutia. (US), W. L. Gore & Associates, Inc. (US), Meril Lifesciences Pvt.Ltd (India), Fujifilm Holdings Corporation (Japan), Vascudyne, Inc. (US), BICO - THE BIO CONVERGENCE COMPANY (Sweden), ReproCELL, Inc. (US), PromoCell GmBH (Germany), Axol Bioscience Ltd. (UK), BPS Bioscience, Inc. (US), Cell Application, Inc. (US), Viscofan DE GmBH (Germany)

To know about the assumptions considered for the study download the pdf brochure

TERUMO CORPORATION (JAPAN)

Terumo Corporation emerges as a prominent player in the cardiac tissue engineering market due to several key factors. Their HeartSheet product, derived from autologous skeletal myoblast sheets, effectively treats heart failure resulting from chronic ischemic disease. This innovation has been strategically bolstered by its approval under Japan's accelerated regulatory framework for regenerative medicine, demonstrating Terumo's commitment to advancing practical applications swiftly. Moreover, Terumo's global presence in over 160 countries ensures widespread accessibility and adoption of their advanced cardiac technologies, reinforcing their leadership in the industry. The company's extensive cardiovascular division specializes not only in developing devices that replicate heart and lung functions during surgery but also in offering comprehensive solutions across various segments like Interventional Systems and Cardiovascular. This integrated approach not only enhances their market position but also underscores Terumo's capability to address diverse aspects of cardiac care, from innovative product development to global distribution and regulatory compliance, solidifying their reputation as a formidable force in cardiac tissue engineering worldwide.

ARTIVION, INC. (US)

Artivion, Inc., formerly CryoLife Inc., stands out as a prominent player in the cardiac tissue engineering market due to its extensive expertise and innovative products tailored for cardiac and vascular surgical procedures, particularly for patients with aortic disease. The company's deep understanding of the complexities involved in cardiac and vascular surgery is exemplified through their flagship product, SynerGraft. This product not only mitigates the risk of immune rejection but also serves as a scaffold that supports natural tissue regeneration, enhancing its effectiveness and biocompatibility. Artivion's strategic presence across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America ensures global accessibility to their advanced medical devices and implantable human tissues. This expansive reach not only facilitates widespread adoption of their innovative solutions but also reinforces their leadership in delivering high-quality products that address critical needs in cardiac care.

BAXTER INTERNATIONAL, INC. (US)

Baxter International Inc. is a prominent player in the cardiac tissue engineering market due to its relentless innovation in medical technology and regenerative therapies. Through its advanced surgery segment, they offers Peri-Guard and Supple Peri-Guard, products designed specifically for cardiothoracic surgery. These products, made from bovine pericardium, boast an exceptionally low adverse event rate of less than 0.07%, highlighting their safety and efficacy. Baxter's extensive global presence across the US, Eastern and Western Europe, the Middle East and Africa, Latin America, Asia, Canada, Japan, Australia, and New Zealand ensures widespread accessibility to their cutting-edge solutions. This broad reach, coupled with their commitment to pushing the boundaries of medical technology, reinforces Baxter's leadership in providing high-quality, effective products for cardiac tissue engineering, thus solidifying their significant role in the market.

Related Reports:

Cardiac Tissue Engineering Market by Material (Scaffold, Stem cells), Product (Heart Valve, Vascular Grafts), Applications (MI,Congenital Heart Disease), End-User (Hospitals & Clinics, Academics & Research Institutes) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]